Evidence map›Paper›PMID 40407598›Full record

ArticleNon-coding RNA2025

Correction: Schlösser et al. Anti-HIV-1 Effect of the Fluoroquinolone Enoxacin and Modulation of Pro-Viral hsa-miR-132 Processing in CEM-SS Cells.

Verena Schlösser, Helen Louise Lightfoot, Christine Leemann, Seyedeh Elnaz Banijamali, Aathma Merin Bejoy, Shashank Tiwari, Jeffrey L Schloßhauer, Valentina Vongrad, Andreas Brunschweiger, Jonathan Hall and 2 more

Abstract readPublished Erratum
In one paragraph

Article in Non-coding RNA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Verena SchlösserInstitute of Pharmaceutical Sciences, ETH Zurich, 8093 Zurich, Switzerland.ORCID 0000-0001-5734-1234
Helen Louise LightfootInstitute of Pharmaceutical Sciences, ETH Zurich, 8093 Zurich, Switzerland.
Christine LeemannDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
Seyedeh Elnaz BanijamaliMax Planck Institute of Molecular Physiology, Chemical Genomics Centre, 44227 Dortmund, Germany.
Aathma Merin BejoyMax Planck Institute of Molecular Physiology, Chemical Genomics Centre, 44227 Dortmund, Germany.
Shashank TiwariMax Planck Institute of Molecular Physiology, Chemical Genomics Centre, 44227 Dortmund, Germany.
Jeffrey L SchloßhauerMax Planck Institute of Molecular Physiology, Chemical Genomics Centre, 44227 Dortmund, Germany.
Valentina VongradDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
Andreas BrunschweigerInstitute of Pharmaceutical Sciences, ETH Zurich, 8093 Zurich, Switzerland.
Jonathan HallInstitute of Pharmaceutical Sciences, ETH Zurich, 8093 Zurich, Switzerland.
Karin J MetznerDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.ORCID 0000-0003-4862-1503
Jochen ImigInstitute of Pharmaceutical Sciences, ETH Zurich, 8093 Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Seyedeh Elnaz Banijamali was not included as an author in the original publication [...].

Identifiers

PMID40407598
PMCPMC12101254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.